Saturday 17 October 2026 Export WVE’s income statement to Excel — free account

WAVE Life Sciences Ltd.

In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.12 0.07 −2.19%

Follow WVE

Alert me

Market cap: $628.6M
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 3/9
Altman Z: 11.34
Beneish M: −2.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 82.56

Total sells 16.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	1	—	—	1	—	—	—	—	—	—	—
Sell	1	8	1	5	—	—	—	—	—	4	—	—

Insider Ownership 19.04%

Capital & Financial Ratios $m

Market Cap 628.58

Revenue 65.37

Net Income (202.47)

Free Cash Flow (193.15)

Net Debt (490.60)

Current Ratio 9.99

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.24)

P/S ratio 9.74

P/B ratio 1.40

Past 5Y EPS Growth —

This Y EPS Growth 6.91%

Next Y EPS Growth (15.52%)

Next Y revenue growth 18.43%

Next 5Y EPS Growth (1.93%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.16%

10-year low 10-year high

P/B against its own 10 years 2.81%

10-year low 10-year high

EV/Sales against its own 10 years 6.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	200	302	602	491
Receivables	21	1	1	1
Inventory	—	—	—	—
Other	4	7	3	4
	235	320	615	508

	2023	2024	2025	Q'26
Payables	13	16	16	20
ST’ Debt	—	—	—	—
Other	—	—	—	—
	186	111	95	51

Compound Annual Growth %

	10y	5y	3y
Sales	75.75%	16.31%	127.08%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	12.38%	44.33%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	38	2	—	—	—
’25	9	9	8	17	43
’24	13	20	—	84	108
’23	13	22	49	29	113
’22	2	0	0	1	4
’21	—	3	36	2	41
’20	4	3	3	9	20

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(60)	(54)	—	—	—
’25	(63)	(46)	(45)	(34)	(187)
’24	(33)	(27)	(46)	(44)	(151)
’23	86	(37)	(34)	(33)	(19)
’22	(40)	(29)	(26)	(33)	(128)
’21	(44)	(9)	(28)	(7)	(89)
’20	(26)	(38)	(20)	(31)	(116)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(60)	(54)	—	—	—
’25	(63)	(46)	(45)	(34)	(188)
’24	(34)	(28)	(47)	(44)	(152)
’23	85	(37)	(35)	(34)	(21)
’22	(40)	(29)	(26)	(34)	(129)
’21	(44)	(10)	(28)	(7)	(90)
’20	(27)	(38)	(20)	(32)	(117)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.34)	—	—	—
’25	(0.29)	(0.31)	(0.32)	(0.30)	(1.21)
’24	(0.24)	(0.25)	(0.47)	0.17	(0.70)
’23	(0.27)	(0.20)	0.07	(0.15)	(0.54)
’22	(0.62)	(0.62)	(0.42)	(0.47)	(2.05)
’21	(0.86)	(0.78)	(0.12)	(0.61)	(2.36)
’20	(1.38)	(1.15)	(0.86)	(0.59)	(3.82)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.95	15.15	31.65	7.78	6.61	3.07	1.16	3.15	3.50	5.28	Analyst estimates 2026–2028 Powerpack
	High	40.15	39.70	56.00	48.64	19.98	12.17	7.09	7.12	16.74	21.73
People
People	Employees	96	168	250	301	220	238	252	268	288	317
	Revenue/emp, $m	0.01	0.02	0.06	0.05	0.09	0.17	0.01	0.42	0.38	0.13
Income, $m
Income, $m	Revenue	1	4	14	16	20	41	4	113	108	43
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(55)	(101)	(147)	(194)	(151)	(122)	(161)	(58)	(97)	(204)
	EBT margin, %	(5,052.93)	(2,597.95)	(1,016.96)	(1,211.52)	(750.86)	(298.92)	(4,416.06)	(51.36)	(89.57)	(478.33)
	Net income	(56)	(102)	(147)	(194)	(150)	(122)	(162)	(58)	(97)	(204)
	Depreciation	1	2	5	9	10	10	10	9	9	9
Per share, $
Per share, $	Revenue	0.05	0.15	0.50	0.47	0.51	0.79	0.05	1.07	0.78	0.25
	Earnings	(2.43)	(3.85)	(5.06)	(5.72)	(3.82)	(2.36)	(2.05)	(0.54)	(0.70)	(1.21)
	Cash flow	(1.40)	(3.16)	(0.79)	(5.56)	(2.96)	(1.72)	(1.62)	(0.18)	(1.09)	(1.11)
	Capex	(0.24)	(0.71)	(0.34)	(0.12)	(0.03)	(0.01)	(0.02)	(0.01)	(0.01)	0.00
	Free cash flow	(1.64)	(3.87)	(1.13)	(5.67)	(2.99)	(1.73)	(1.64)	(0.19)	(1.10)	(1.12)
	Book value	6.26	5.56	2.53	1.88	2.11	0.63	(0.57)	0.37	1.52	3.07
	Shares, m	23	27	29	34	39	52	79	106	138	169
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	547.06	237.00	84.49	16.99	15.38	3.23	133.98	5.00	15.79	67.10
	P/B	4.43	6.61	16.60	4.26	3.73	5.01	0.00	14.30	8.16	5.53
	EV/Sales	409.44	200.40	72.37	7.79	6.19	0.24	109.74	3.23	13.00	53.01
	EV/FCF	(11.93)	(7.61)	(31.80)	(0.65)	(1.06)	(0.14)	(3.10)	(17.82)	(9.27)	(12.03)
Cash, $m
Cash, $m	Operating cash flow	(32)	(84)	(23)	(188)	(116)	(89)	(128)	(19)	(151)	(187)
	Capex	(6)	(19)	(10)	(4)	(1)	(1)	(1)	(1)	(1)	(1)
	Free cash flow	(37)	(103)	(33)	(192)	(117)	(90)	(129)	(21)	(152)	(188)
Balance, $m
Balance, $m	Working capital	140	132	72	67	109	98	27	49	209	520
	Total debt	0	3	9	29	26	25	32	—	—	—
	Net debt	(150)	(143)	(175)	(147)	(184)	(151)	(88)	(200)	(302)	(602)
	Shareholders’ equity	143	147	73	64	83	32	(45)	40	210	518
Returns, %
Returns, %	ROA	(33.71)	(58.84)	(61.39)	(66.75)	(53.21)	(50.28)	(91.58)	(27.30)	(30.94)	(41.26)
	ROIC	0.00	(1,284.77)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(38.61)	(74.31)	(137.73)	(282.52)	(204.64)	(212.09)	2,570.05	2,106.32	(77.87)	(56.16)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
AVTX Avalo Therapeutics, Inc.	$644.1M	— (loss-making)	— (loss-making)	−70.14% (below 0%: shrinking)	n/m	+75.70% (above 0%: growing)	55.73%	0.00%	Compare
WVE WAVE Life Sciences Ltd.	$628.6M	— (loss-making)	— (loss-making)	−73.88% (below 0%: shrinking)	n/m	−17.59% (below 0%: shrinking)	100.00%	(3,248.33%)
CLYM Climb Bio, Inc.	$626.6M	— (loss-making)	—	—	n/m	+3.73% (above 0%: growing)	—	0.00%	Compare
NVCT Nuvectis Pharma, Inc.	$618.0M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%	Compare
SLDB Solid Biosciences Inc.	$615.5M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−39.56% (below 0%: shrinking)	0.00%	0.00%	Compare
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%	Compare
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
Median of peers	$622.3M	—	—	+3.50%	—	+4.07%	67.70%	0.00%

All 614 Biotechnology stocks →